제네릭 의약품 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 용도별, 약물전달별, 형태별, 공급원별, 유통 채널별, 지역별, 경쟁별 예측(2020-2030년)

Generic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Drug Delivery, By Form, By Source, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,497,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,940,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,550,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

제네릭 의약품 세계 시장 규모는 2024년에 4,434억 4,000만 달러로 평가되었고, 예측 기간으로는 2030년까지 연평균 복합 성장률(CAGR) 6.27%로 안정된 성장이 예측됩니다.

세계 제네릭 의약품 시장은 만성 질환 증가, 의료비 증가, 저렴한 치료 옵션의 필요성 등 몇 가지 주요 요인에 의해 주도되고 있습니다. 제네릭 의약품은 오리지널 의약품을 대체할 수 있는 비용 효율적인 대안을 제공하여 더 많은 사람들이 이용할 수 있도록 합니다. 오리지널 의약품의 특허가 만료되면 제네릭 제약사가 시장에 진입할 수 있는 기회가 생기고, 경쟁이 치열해져 가격이 하락합니다. 의료비 절감을 위해 제네릭 의약품 사용을 장려하는 정부의 이니셔티브는 시장 성장을 더욱 촉진할 것입니다. 생물학적 제제의 제네릭 의약품에 대한 수요 증가와 신흥 시장의 제네릭 의약품 생산 능력 확대도 시장 확대에 기여하고 있습니다. 세계 제네릭 의약품 시장은 저렴한 가격, 접근성, 시장 경쟁으로 인해 지속적인 성장이 예상됩니다. 제네릭 의약품과 바이오시밀러가 미국 전체 의료비 지출에서 차지하는 비중은 1.2%에 불과해 비용 대비 효율성이 뛰어납니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	4,434억 4,000만 달러
시장 규모 : 2030년	6,408억 8,000만 달러
CAGR : 2025-2030년	6.27%
급성장 부문	저분자 제네릭 의약품
최대 시장	북미

시장 성장 촉진요인

비용 효율적이고 저렴한 가격

시장 과제

규제 장애물 및 승인 절차

주요 시장 동향

제네릭 생물학적 제제(바이오시밀러)의 진보

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 제네릭 의약품 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 유형별(저분자 제네릭 의약품, 바이오시밀러)
  • 용도별(심혈관질환, 당뇨병, 신경학, 종양학, 항염증 질환, 기타)
  • 약물전달(경구, 국소, 비경구, 기타)
  • 형태별(정제, 캡슐, 주사제, 기타)
  • 공급원별(사내, 계약 제조 조직)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 제네릭 의약품 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 제네릭 의약품 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 이탈리아
  • 프랑스
  • 스페인

제8장 아시아태평양의 제네릭 의약품 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 남미의 제네릭 의약품 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 제네릭 의약품 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시

제13장 Porter의 Five Forces 분석

• 산업내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• STADA Arzneimittel AG
• Aurobindo Pharma Limited
• Dr Reddy's Laboratories Ltd.
• Cipla Ltd.
• Novo Nordisk A/S
• Abbott Laboratories Inc.
• Endo International plc
• Sanofi S.A.
• Aspen Pharmacare Holdings Limited
• Lupin Limited

제15장 전략적 제안

제16장 회사 소개 및 면책조항

LSH

영문 목차

영문목차

Global Generic Drugs Market was valued at USD 443.44 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 6.27% through 2030. The Global Generic Drugs Market is primarily driven by several key factors, including the rising prevalence of chronic diseases, increasing healthcare costs, and the need for affordable treatment options. Generic drugs offer a cost-effective alternative to brand-name medications, making them accessible to a broader population. Patent expirations of branded drugs create opportunities for generic manufacturers to enter the market, leading to increased competition and lower prices. Government initiatives promoting the use of generic drugs to reduce healthcare expenditures further fuel market growth. The growing demand for generic versions of biologic drugs and the expansion of generic drug manufacturing capabilities in emerging markets also contribute to the market's expansion. The Global Generic Drugs Market is poised for sustained growth driven by affordability, accessibility, and market competition. Generics and biosimilars represent just 1.2% of total U.S. healthcare spending, underscoring their cost-effectiveness.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 443.44 Billion
Market Size 2030	USD 640.88 Billion
CAGR 2025-2030	6.27%
Fastest Growing Segment	Small Molecule Generics
Largest Market	North America

Key Market Drivers

Cost-effectiveness and Affordability

The affordability and accessibility of generic drugs compared to their brand-name counterparts constitute a pivotal factor driving their widespread adoption and market expansion on a global scale. Generic medications, renowned for their lower price points, serve as indispensable alternatives for patients and healthcare systems grappling with constrained budgets or exorbitant out-of-pocket expenses associated with branded pharmaceuticals. In regions where healthcare resources are scarce or where patients bear a substantial burden of medication costs, the cost-effectiveness of generic drugs emerges as a cornerstone of healthcare provision. The considerable price differentials between generic and brand-name medications facilitate broader access to essential treatments, ensuring that individuals can afford the medications they need to manage their health conditions effectively.

A fundamental driver of the cost-effectiveness of generic drugs lies in the expiration of patents on brand-name medications. Upon patent expiry, generic manufacturers gain the legal right to produce and distribute equivalent versions of the drug, igniting competition within the pharmaceutical market. This competitive landscape fosters price reductions as generic manufacturers leverage economies of scale, streamlined production processes, and reduced research and development costs to offer their products at significantly lower prices.

Key Market Challenges

Regulatory Hurdles and Approval Processes

One of the primary challenges confronting the Global Generic Drugs Market is navigating the complex regulatory landscape governing generic drug approval processes. Regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others, enforce stringent standards and requirements for the approval of generic medications. Generic manufacturers must demonstrate bioequivalence, pharmaceutical equivalence, and therapeutic equivalence to the reference brand-name drug through comprehensive analytical and clinical studies. The regulatory pathway for generic drug approval often entails navigating intricate legal frameworks, conducting extensive pharmacokinetic and pharmacodynamic studies, and adhering to stringent quality assurance standards, all of which pose formidable barriers to entry for manufacturers. Disparities in regulatory requirements between different regions and countries necessitate meticulous compliance with diverse regulatory mandates, adding complexity and uncertainty to the generic drug approval process.

Key Market Trends

Advancements in Generic Biologics (Biosimilars)

The emergence of biosimilars heralds a transformative paradigm shift within the pharmaceutical landscape, ushering in a new era of accessibility, affordability, and innovation in biologic drug therapy. Biosimilars, colloquially referred to as generic versions of biologic drugs, constitute a rapidly burgeoning segment of the generic drugs market, poised to revolutionize the treatment landscape across a diverse array of therapeutic domains. This paradigmatic evolution is underpinned by significant advancements in biotechnology and regulatory frameworks governing biosimilar approval, which collectively catalyze the development, commercialization, and widespread adoption of biosimilar therapies as compelling alternatives to their costly brand-name counterparts. In 2023, the average out-of-pocket cost for a generic drug was USD 7.05, compared to $27.10 for a brand-name drug.

The ascendancy of biosimilars as a burgeoning force within the generic drugs market is predicated upon the intricate interplay between scientific innovation and regulatory harmonization. Pioneering breakthroughs in biotechnological methodologies have empowered manufacturers to elucidate the complex structural and functional attributes of biologic drugs with unparalleled precision and fidelity, thereby facilitating the rational design and engineering of biosimilar formulations that closely mimic the reference biologic products. Leveraging state-of-the-art analytical techniques, manufacturers can meticulously characterize the physicochemical properties, pharmacokinetic profiles, and immunogenicity profiles of biosimilars, ensuring their comparability to the reference biologic drugs with utmost rigor and scientific rigor.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.
• Fresenius Kabi AG
• STADA Arzneimittel AG
• Aurobindo Pharma Limited
• Dr Reddy's Laboratories Ltd.
• Cipla Ltd.
• Novo Nordisk A/S
• Abbott Laboratories Inc.
• Endo International plc
• Sanofi S.A.
• Aspen Pharmacare Holdings Limited
• Lupin Limited

Report Scope:

In this report, the Global Generic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Generic Drugs Market, By Type:

• Small Molecule Generics
• Biosimilars

Generic Drugs Market, By Application:

• Cardiovascular Diseases
• Diabetes
• Neurology
• Oncology
• Anti-Inflammatory Diseases
• Others

Generic Drugs Market, By Drug Delivery:

• Oral
• Topical
• Parenteral
• Others

Generic Drugs Market, By Form:

• Tablet
• Capsule
• Injection
• Others

Generic Drugs Market, By Source:

• In House
• Contract Manufacturing Organizations

Generic Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Generic Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Generic Drugs Market.

Available Customizations:

Global Generic Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Generic Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Small Molecule Generics and Biosimilars)
  • 5.2.2. By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Anti-Inflammatory Diseases, Others)
  • 5.2.3. By Drug Delivery (Oral, Topical, Parenteral, Others)
  • 5.2.4. By Form (Tablet, Capsule, Injection, Others)
  • 5.2.5. By Source (In House and Contract Manufacturing Organizations)
  • 5.2.6. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2024)
• 5.3. Market Map

6. North America Generic Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Drug Delivery
  • 6.2.4. By Form
  • 6.2.5. By Source
  • 6.2.6. By Distribution Channel
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Generic Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Drug Delivery
      • 6.3.1.2.4. By Form
      • 6.3.1.2.5. By Source
      • 6.3.1.2.6. By Distribution Channel
  • 6.3.2. Canada Generic Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Drug Delivery
      • 6.3.2.2.4. By Form
      • 6.3.2.2.5. By Source
      • 6.3.2.2.6. By Distribution Channel
  • 6.3.3. Mexico Generic Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Drug Delivery
      • 6.3.3.2.4. By Form
      • 6.3.3.2.5. By Source
      • 6.3.3.2.6. By Distribution Channel

7. Europe Generic Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Drug Delivery
  • 7.2.4. By Form
  • 7.2.5. By Source
  • 7.2.6. By Distribution Channel
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Generic Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Drug Delivery
      • 7.3.1.2.4. By Form
      • 7.3.1.2.5. By Source
      • 7.3.1.2.6. By Distribution Channel
  • 7.3.2. United Kingdom Generic Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Drug Delivery
      • 7.3.2.2.4. By Form
      • 7.3.2.2.5. By Source
      • 7.3.2.2.6. By Distribution Channel
  • 7.3.3. Italy Generic Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Drug Delivery
      • 7.3.3.2.4. By Form
      • 7.3.3.2.5. By Source
      • 7.3.3.2.6. By Distribution Channel
  • 7.3.4. France Generic Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Drug Delivery
      • 7.3.4.2.4. By Form
      • 7.3.4.2.5. By Source
      • 7.3.4.2.6. By Distribution Channel
  • 7.3.5. Spain Generic Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Drug Delivery
      • 7.3.5.2.4. By Form
      • 7.3.5.2.5. By Source
      • 7.3.5.2.6. By Distribution Channel

8. Asia-Pacific Generic Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Drug Delivery
  • 8.2.4. By Form
  • 8.2.5. By Source
  • 8.2.6. By Distribution Channel
  • 8.2.7. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Generic Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Drug Delivery
      • 8.3.1.2.4. By Form
      • 8.3.1.2.5. By Source
      • 8.3.1.2.6. By Distribution Channel
  • 8.3.2. India Generic Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Drug Delivery
      • 8.3.2.2.4. By Form
      • 8.3.2.2.5. By Source
      • 8.3.2.2.6. By Distribution Channel
  • 8.3.3. Japan Generic Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Drug Delivery
      • 8.3.3.2.4. By Form
      • 8.3.3.2.5. By Source
      • 8.3.3.2.6. By Distribution Channel
  • 8.3.4. South Korea Generic Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Drug Delivery
      • 8.3.4.2.4. By Form
      • 8.3.4.2.5. By Source
      • 8.3.4.2.6. By Distribution Channel
  • 8.3.5. Australia Generic Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Drug Delivery
      • 8.3.5.2.4. By Form
      • 8.3.5.2.5. By Source
      • 8.3.5.2.6. By Distribution Channel

9. South America Generic Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Drug Delivery
  • 9.2.4. By Form
  • 9.2.5. By Source
  • 9.2.6. By Distribution Channel
  • 9.2.7. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Generic Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Drug Delivery
      • 9.3.1.2.4. By Form
      • 9.3.1.2.5. By Source
      • 9.3.1.2.6. By Distribution Channel
  • 9.3.2. Argentina Generic Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Drug Delivery
      • 9.3.2.2.4. By Form
      • 9.3.2.2.5. By Source
      • 9.3.2.2.6. By Distribution Channel
  • 9.3.3. Colombia Generic Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Drug Delivery
      • 9.3.3.2.4. By Form
      • 9.3.3.2.5. By Source
      • 9.3.3.2.6. By Distribution Channel

10. Middle East and Africa Generic Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Drug Delivery
  • 10.2.4. By Form
  • 10.2.5. By Source
  • 10.2.6. By Distribution Channel
  • 10.2.7. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Generic Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Drug Delivery
      • 10.3.1.2.4. By Form
      • 10.3.1.2.5. By Source
      • 10.3.1.2.6. By Distribution Channel
  • 10.3.2. Saudi Arabia Generic Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Drug Delivery
      • 10.3.2.2.4. By Form
      • 10.3.2.2.5. By Source
      • 10.3.2.2.6. By Distribution Channel
  • 10.3.3. UAE Generic Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Drug Delivery
      • 10.3.3.2.4. By Form
      • 10.3.3.2.5. By Source
      • 10.3.3.2.6. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Teva Pharmaceutical Industries Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Sandoz International GmbH
• 14.3. Viatris Inc.
• 14.4. Sun Pharmaceutical Industries Ltd.
• 14.5. Fresenius Kabi AG
• 14.6. STADA Arzneimittel AG
• 14.7. Aurobindo Pharma Limited
• 14.8. Dr Reddy's Laboratories Ltd.
• 14.9. Cipla Ltd.
• 14.10. Novo Nordisk A/S
• 14.11. Abbott Laboratories Inc.
• 14.12. Endo International plc
• 14.13. Sanofi S.A.
• 14.14. Aspen Pharmacare Holdings Limited
• 14.15. Lupin Limited

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료